The Role of the Pharmacist in T2D: The Evolution of Insulin Therapy

The Role of the Pharmacist in T2D: The Evolution of Insulin Therapy
Launch Date:
January 18, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:


Relevant Terms:

Type 2 diabetes; insulin therapy

Joshua J. Neumiller, PharmD, CDE, FASCP

Joshua J. Neumiller, PharmD, CDE, FASCP
Vice-Chair & Associate Professor, Department of Pharmacotherapy
Director of Experiential Services
Editor-in-Chief, Diabetes Spectrum
Washington State University, College of Pharmacy
Spokane, WA

Dr. Neumiller is an associate professor of pharmacotherapy at the Washington State University College of Pharmacy. He is a member of the WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller received a Bachelor of Science, magna cum laude, in 2003, and a Doctor of Pharmacy, magna cum laude, in 2005, from Washington State University. He completed a specialty residency in geriatrics in 2007, and a clinical research fellowship with an emphasis in endocrinology in 2008, both at Washington State University. Neumiller is a certified diabetes educator (CDE) and a fellow of the American Society of Consultant Pharmacists (FASCP).
Dr. Neumiller’s research interests focus on issues involving the management of chronic diseases such as diabetes and chronic kidney disease. He is also active in research surrounding medication safety during transitions of care. Neumiller’s research, commentaries, and reviews have appeared in numerous journals including: Diabetes Care, American Journal of Kidney Disease, American Journal of Health-Systems Pharmacy, Current Therapeutic Research, and Clinical Therapeutics, among others.

Dr. Neumiller was the recipient of the Achievement Reward for College Scientists from the ARCS Foundation in 2006, the Pharmacist’s Mutual Distinguished Young Pharmacist of the Year Award in 2009, the Golden Apple Award for Teaching Excellence from the MEDEX Northwest Division of Physician Assistant Studies, School of Medicine, University of Washington in 2009, and the American Foundation for Pharmaceutical Education Pharmacy Faculty Fellowship in Geriatrics in 2010. He is currently the editor-in-chief for the American Diabetes Association (ADA) journal Diabetes Spectrum.

Candis M. Morello, PharmD, CDE, FCSHP, FASHP

Candis M. Morello, PharmD, CDE, FCSHP, FASHP
Professor of Clinical Pharmacy
Associate Dean for Student Affairs
University of California San Diego
Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, CA

Dr. Candis Morello is founding faculty, Professor of Clinical Pharmacy, and Associate Dean for Student Affairs at the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. After earning her PharmD from UC San Francisco in 1996, she completed a Pharmacy Practice Residency with a Geriatrics Emphasis at the VA San Diego Healthcare System. Dr. Morello is a Certified Diabetes Educator and Clinical Pharmacist Specialist who directs a Diabetes Intense Medical Management Clinic at the VA in San Diego. 
Dr. Morello's research program involves exploring both clinical outcomes in diabetes patients and educational outcomes in student pharmacists who attend her diabetes educational programs. Dr. Morello maintains a clinical practice at the Veterans Affairs San Diego Health System where she is Director of the Diabetes Intense Medical Management Clinic. She is studying the effect of pharmacist-run diabetes medication management services on the 1) metabolic, 2) quality of life, 3) patient satisfaction 4) adherence rate outcomes in diabetes patients, 5) pharmacoeconomics and 6) medication complexity.
Dr. Morello is nationally known for academic excellence as a diabetes clinician and researcher. She has authored numerous articles, book chapters, and abstracts all centered on diabetes and she serves as a reviewer for prestigious publications.
1. Summarize the current evidence-based practice guidelines for the management of type 2 diabetes (T2D).
2. Describe barriers to insulin initiation and insulin intensification in patients with T2D.
3. Review strategies to overcome barriers to successful insulin initiation and intensification.
4. Describe the current and new insulin therapies and those in late-stage development for the management of T2D.


Joshua J. Neumiller, PharmD, CDE, FASCP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
Candis M. Morello, PharmD, CDE, FCSHP, FASHP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education (CE) activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
 In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this knowledge based CPE activity (J0000275-0000-18-003-H01-P) for 1 contact hours for pharmacists.
UAN: J0000275-0000-18-003-H01-P
Credits: 1.0 hour (0.10 ceu)
Published: January 18, 2018
Expires: January 18, 2019
Type of Activity: Knowledge
Media: Internet
Estimated time to complete activity: 60 minutes
Fee Information: There is no fee for this educational activity.

During the period January 18, 2018 through January 18, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. 
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Rush University Medical Center, MCM Education, Boehringer Ingelheim Pharmaceuticals, Inc., or Lilly USA, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.